Momenta Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Goldman Sachs Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
August 6, 2015 6:59 AM EDTGoldman Sachs downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Buy to Neutral with a price target of $27 (unchanged).
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $23.12 yesterday.
... MoreCowen Raises Price Target on Momenta Phama (MNTA) Following 2Q Results
August 5, 2015 9:57 AM EDTCowen reiterated a Market Perform rating on Momenta Pharmaceuticals (NASDAQ: MNTA), and raised the price target to $23.00 (from $18.00), following 2Q results. MNTA reported 2Q EPS of ($0.04) vs consensus of ($0.19).
Analyst Ritu Baral commented, "Investor focus remains Glatopa sales. Early launch looks... More
Momenta Pharmaceuticals (MNTA) PT Raised to $26 at Leerink Partners
August 5, 2015 7:58 AM EDTLeerink Partners analyst Jason Gerberry bumped his price target on Outperform-rated Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $25.00) following Q2 results.
Gerberry commented, "... MNTA reported better-than-expected top-line revenue of ~$45m vs our est of ~$7m driven by better-than-expected revenue recognition from Glatopa... More
